|Over a quarter ago|
Dova treatment of chemotherapy-induced thrombocytopenia granted orphan status » 12:0312/2012/20/19
Dova Pharmaceuticals' treatment of chemotherapy-induced thrombocytopenia was granted FDA orphan designation, according to a post to the agency's website. Reference Link
Three new option listings and two option delistings on November 13th » 08:3011/1311/13/19
CNST, INSW, DF, DOVA
New option listings for…
New option listings for November 13th include Constellation Pharmaceuticals Inc (CNST), Dean Foods Company New (DFODQ), and International Seaways (INSW). Option delistings effective November 13th include Dean Foods Company New (DF) and Dova Pharmaceuticals Inc (DOVA).
Largest borrow rate increases among liquid names » 08:4510/2810/28/19
HOME, AM, OSTK, HIIQ, JNUG, DOVA, NEPT, UUUU, MT
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: At Home Group (HOME) 1.47% +0.98, Antero Midstream (AM) 35.80% +0.95, Overstock com (OSTK) 16.06% +0.60, Health Insurance Innovations (HIIQ) 34.10% +0.52, Direxion Junior Gold (JNUG) 1.26% +0.35, Dova Pharmaceuticals (DOVA) 8.27% +0.33, Neptune Technologies (NEPT) 19.48% +0.27, Energy Fuels (UUUU) 6.62% +0.24, ArcelorMittal (MT) 0.83% +0.15, and Proshares Ultrapro 3x Crude Oil ETF (OILU) 2.52% +0.10.
Dova Pharmaceuticals moved to Not Rated at Oppenheimer » 07:3110/0910/09/19
Oppenheimer analyst Justin Kim moved to Not Rated from Outperform on Dova Pharmaceuticals following Swedish Orphan Biovitrum's offer to acquire the company. The analyst believes there is limited merger risk exists for the deal, noting that Swedish Orphan Biovitrum holds the right commercial footprint, without significant overlap to trigger FTC complications.
Dova Pharmaceuticals downgraded to Neutral from Outperform at Wedbush » 07:2910/0410/04/19
Wedbush analyst Laura…
Wedbush analyst Laura Chico downgraded Dova Pharmaceuticals to Neutral from Outperform but raised her price target to $29 from $24 following the announcement of an acquisition bid by Swedish Orphan Biovitrum. Chico tells investors in a research note that she sees limited room for upside with the stock now trading above $28.
Fly Intel: Top five analyst upgrades » 10:1910/0310/03/19
RTN, WIT, DOVA, OKTA, CRWD, NEM
Catch up on today's…
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Raytheon (RTN) upgraded to Outperform from Neutral at Credit Suisse WITH analyst Robert Spingarn saying he believes United Technologies' (UTX) aerospace businesses are undervalued and that the market has yet to appropriately discount Raytheon's ~43.1% ownership of the proposed combined entity. 2. Wipro (WIT) upgraded to Neutral from Sell at Goldman Sachs with analyst Sumeet Jain citing valuation. 3. Dova Pharmaceuticals (DOVA) upgraded to Neutral from Underweight at JPMorgan with analyst Joel Fishbein saying the company's "strong" execution continues to drive "impressive growth at scale" as customer deal sizes grow amid larger initial deployments and customers adopting multiple products. 4. Crowdstrike (CRWD) upgraded to Buy from Hold at SunTrust with analyst Joel Fishbein saying the company has developed a "category-defining" cloud platform for cyber security, a market that is "ripe for disruption." 5. Newmont Goldcorp (NEM) upgraded to Buy from Hold at Deutsche Bank with analyst Chris Terry saying shares of Newmont have significantly underperformed compared to its closest peer Barrick Gold (GOLD) and also versus the gold price. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Dova Pharmaceuticals downgraded to Neutral from Buy at Ladenburg » 06:4810/0310/03/19
Ladenburg Thalmann analyst Matthew Kaplan downgraded Dova Pharmaceuticals to Neutral from Buy and lowered his price target for the shares to $29 from $32. The analyst cites the terms of Dova's agreement to be acquired by Swedish Orphan Biovitrum AB for the downgrade.
Dova Pharmaceuticals upgraded to Neutral from Underweight at JPMorgan » 04:4710/0310/03/19
JPMorgan analyst Anupam…
JPMorgan analyst Anupam Rama upgraded Dova Pharmaceuticals to Neutral from Underweight and raised his price target for the shares to $28 from $16 after the company reached an agreement to acquired by Swedish Orphan Biovitrum.
Fly Intel: Wall Street's top stories for Monday » 16:4309/3009/30/19
AAPL, BA, DOVA, CLNY, AMZN, JE, THO, GTHX, IMMU
Stocks regained some of…
Fly Intel: Wall Street's top stories at midday » 12:2309/3009/30/19
AAPL, BA, DOVA, SGEN, THO, GTHX, IMMU
Stocks have been modestly…